Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0247-0829 · 1 trial · 2 indications
Number of events
Number of events
| Arm | Type | Description |
|---|---|---|
| Active treatment NNC0247-0829 | EXPERIMENTAL | Up to 6 single dose cohorts are planned with 10 subjects in each; 8 will receive active treatment. Up to 2 multiple dose cohorts are planned with 12 subjects in each; 8 will receive active treatment |
| Placebo | PLACEBO_COMPARATOR | In each of the 6 single dose cohorts, 2 subjects will receive placebo. In the 2 multiple dose cohorts, 4 subjects will receive placebo |
| Name | Type | Description |
|---|---|---|
| NNC0247-0829 | DRUG | Participants will receive either single or multiple doses given subcutaneously (s.c., under the skin) in a lifted fold of the stomach skin. Dose level and number of doses will depend on the cohort. |
| Placebo (NNC0247-0829) | DRUG | Participants will receive either single or multiple doses of placebo given s.c. in a lifted fold of the stomach skin. |
Inclusion Criteria: * Female not of childbearing potential (CBP) or male, aged 18-60 years (both inclusive) at the time of signing informed consent. * Body mass index (BMI) between 27.0 and 34.9 kg/m\^2 (both inclusive) in the SD cohorts and between 27.0 and 39.9 kg/m\^2 (both inclusive) in the MD ...
NNC0247-0829 is an investigational small molecule being developed for weight management in people with overweight or obesity. It is being studied as a treatment for overweight, a metabolic condition. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
NNC0247-0829 is being developed by Novo Nordisk A/S, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVO. The company is conducting clinical research on this investigational drug for weight management in individuals with overweight or obesity.
NNC0247-0829 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being evaluated in clinical trials. The drug is being studied for weight management in people with overweight or obesity.
NNC0247-0829 has one completed clinical trial, NCT04010786, which investigated the drug for weight management in people with overweight or obesity. This Phase 1 study enrolled 103 participants in the United States and was randomized, double-blind, and placebo-controlled.
NNC0247-0829 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for weight management in people with overweight or obesity. The drug has completed one clinical trial, but it remains under investigation and has not been authorized for commercial use.